Recital 17, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

To ensure transparency, traceability and professional secrecy, the documentation related to joint scientific consultations on medicinal products should be sent in a digital format and should be exchanged with and between the Coordination Group, the JSC Subgroup, the HTA Secretariat, the health technology developer, and individual experts during joint scientific consultations on medicinal products through the HTA IT platform.